Arena Pharmaceuticals (ARNA) 4.51 $ARNA Will Arena

New Post Public Reply Private Reply Replies (0) Message Board

Feb 28, 2015 at 7:28 PM

Arena Pharmaceuticals (ARNA) 4.51 $ARNA

Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 3:22PM CST
Arena Pharmaceuticals (ARNA) is scheduled to report fourth-quarter 2014 results on Mar 2.
AMRN: 1.51 (+0.05), PETX: 19.26 (+0.03), ARNA: 4.51 (-0.24)

Arena's Belviq Prescriptions Hold Up During Presidents' Day Holiday Week
Clinically Sound Investor - at Seeking Alpha - Fri Feb 27, 1:58PM CST

ARNA: 4.51 (-0.24)

Lessons From A Dozen Years Of Short Selling
Whitney Tilson - Seeking Alpha - Fri Feb 27, 9:39AM CST
(Editor's Note: Long-time contributor Whitney Tilson developed a presentation titled "Lessons from a Dozen Years of Short Selling" that he's presented at a handful of investment conferences in New York City. With his permission, we're now...
MBI: 9.00 (-0.04), FCEL: 1.31 (+0.06), HLF: 31.01 (-3.81), AFC: 25.59 (+0.14), VJET: 8.91 (+0.05), LL: 51.86 (+2.63), BLDP: 2.29 (-0.07), NSR: 26.52 (-0.14), TXTR: 28.21 (-0.48), RPTP: 9.27 (-0.37), LNKD: 267.20 (-3.56), ONVO: 5.92 (-0.14), XONE: 15.13 (-0.40), ARNA: 4.51 (-0.24), AGM: 31.94 (+0.35), PLUG: 3.08 (-0.03), FB: 78.97 (-1.44), DDD: 30.47 (+0.41), DECK: 74.24 (+0.50), TRIP: 89.25 (-0.61), CSLT: 7.29 (-0.21), LRN: 16.93 (unch), PCLN: 1,237.48 (-3.77), NFLX: 474.91 (-8.12), CROX: 11.15 (+0.46), CALL: 7.72 (+0.18), WRLD: 82.11 (-1.09), SODA: 17.92 (+0.66)

Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 34.94 (-0.30), CASM: 1.29 (+0.02), AMRN: 1.51 (+0.05), XON: 41.06 (-1.86), OSIR: 17.27 (-0.07), CPIX: 6.13 (+0.24), AMED: 30.17 (-0.73), CTIC: 2.34 (-0.04), INSY: 60.06 (-0.65), ECYT: 5.80 (-0.11), CMRX: 40.48 (-0.60), KYTH: 41.55 (-1.69), TRIB: 17.76 (-0.21), GALE: 1.80 (-0.03), ARNA: 4.51 (-0.24), XLRN: 40.63 (-0.37), ACRX: 8.86 (-0.10), ENDP: 85.60 (+0.36), DPLO: 30.00 (-0.09), SLXP: 157.20 (+0.25), PPHM: 1.41 (+0.03), MYL: 57.33 (+0.09), CBPO: 76.60 (-0.31), RGEN: 25.71 (-0.49), HALO: 15.07 (-0.21), ALIM: 5.23 (-0.05), ACHN: 12.14 (-0.35), GERN: 3.02 (-0.13), DARA: 0.99 (+0.05), SCMP: 15.38 (-0.62), ICPT: 221.37 (+2.30), CDXS: 3.53 (-0.02), PCRX: 114.77 (-1.22), PBYI: 213.01 (+7.05), FOLD: 8.76 (-0.03)

Orexigen's Q4 Results Disappoint, But Contrave Is Gaining Market Share
Kanak Kanti De - at Seeking Alpha - Thu Feb 26, 3:39PM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch
Brian Orelli, The Motley Fool - Motley Fool - Thu Feb 26, 6:02AM CST
The launch of Orexigen Therapeutics ' obesity drug Contrave was nothing to get too excited about. In the fourth quarter, which included 10 weeks of the launch, net sales of the drug were just $6.5 million, which resulted in $1.3 million in...
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Arena: Belviq Television Ads Resume After 1 Week Hiatus
Spencer Osborne - at Seeking Alpha - Tue Feb 24, 7:11AM CST

OREX: 5.64 (-0.23), ARNA: 4.51 (-0.24)

Orexigen: Contrave Scripts Pass 9,000 - Closing In On Qsymia
Spencer Osborne - at Seeking Alpha - Mon Feb 23, 10:00AM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Arena: Belviq Sales Show Modest Gain - Time To Assess 2015 Expectations?
Spencer Osborne - at Seeking Alpha - Mon Feb 23, 9:33AM CST

OREX: 5.64 (-0.23), NVO: 47.75 (+0.22), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Arena's Belviq Slows At A Bad Time
Clinically Sound Investor - at Seeking Alpha - Mon Feb 23, 8:57AM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus
at The Street - Fri Feb 20, 2:47PM CST
The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 0.94 (unch), AMRN: 1.51 (+0.05), HWAY: 22.38 (-0.37), HLS: 43.46 (-0.62), CYBX: 68.50 (+1.90), ESRX: 84.79 (+0.25), ECYT: 5.80 (-0.11), DXCM: 60.74 (-1.22), NSTG: 10.51 (-0.08), SRPT: 13.90 (+0.08), HZNP: 20.53 (+1.46), MDXG: 10.35 (-0.13), DEPO: 21.95 (-0.65), ANIK: 39.92 (-0.04), NKTR: 13.07 (+0.09), KERX: 12.16 (+0.23), ALIM: 5.23 (-0.05), EPZM: 23.52 (-0.08), AEGR: 27.20 (+0.20), MDRX: 12.01 (-0.74), ELGX: 15.77 (+0.09), NUVA: 45.75 (+0.76), HPTX: 29.55 (+1.82), GNMK: 12.71 (-0.19), MDVN: 117.53 (-2.21), HBIO: 5.46 (-0.09), ACAD: 37.97 (+0.19), ST: 53.74 (+0.09), RPTP: 9.27 (-0.37), FMI: 47.76 (-0.58), GMED: 24.28 (-0.78), JAZZ: 170.09 (-5.10), PTCT: 71.33 (-2.13), INFI: 15.20 (-0.84), ARNA: 4.51 (-0.24), EXEL: 2.93 (unch), NEO: 4.54 (+0.13), EXAS: 22.47 (-0.89), ALKS: 70.25 (-0.98), HTWR: 85.23 (-1.15), MNKD: 6.52 (-0.30), IPXL: 40.29 (-0.41), SQNM: 3.50 (-0.02), HALO: 15.07 (-0.21), ISIS: 68.56 (+1.23), CLVS: 76.46 (-1.43), BIO: 127.18 (+8.18), BIOS: 6.11 (+0.19), PCRX: 114.77 (-1.22)

Orexigen's Contrave Sales Recover - Investors Should Look To Europe
Spencer Osborne - at Seeking Alpha - Wed Feb 18, 11:02AM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Arena's Belviq Scripts Spike - Maintaining This Trajectory Important
Spencer Osborne - at Seeking Alpha - Wed Feb 18, 8:22AM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Arena Pharmaceuticals to Present at the 2015 RBC Capital Markets Healthcare Conference
PR Newswire - Wed Feb 18, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 2015 RBC Capital Markets Healthcare Conference on Tuesday, February 24, 2015, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time), at The New York Palace Hotel in New York City.
ARNA: 4.51 (-0.24)

Vivus' Qsymia Experiencing Both Prescription Growth And Market Share Erosion
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 7:03PM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Orexigen's Contrave Resumes Solid Growth Rate
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 7:45AM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Arena's Belviq Hits New High Prescription Mark, But Needs Similar Future Growth
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 7:42AM CST

ARNA: 4.51 (-0.24)

Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 102.51 (-0.29), OREX: 5.64 (-0.23), ECYT: 5.80 (-0.11), NVO: 47.75 (+0.22), MRK: 58.54 (-0.42), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.64 (-0.23), VRTX: 119.43 (-0.54), NVO: 47.75 (+0.22), VVUS: 2.61 (-0.08), QSII: 17.38 (-0.04), MDRX: 12.01 (-0.74), ARNA: 4.51 (-0.24)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LiberNovo Demos Ergonomic Seating at IFA 2026

Riding the Ergonomic Wave at IFA 2026 No stranger to the innovation spotlight, LiberNovo’s got its eyes on Berlin this time around. As sparks fly at the IFA 2026, they’re rolling out their grand Maxis Series and rubbing shoulders with big names in technology. How does a company shake things up in a sea of tech? Start by thinking big and tall—literally. Maxis Series:...

Why Buyers Are Flocking to Whidbey Island Homes

Something's got folks eyeing Whidbey Island like a gambler with a hot tip—and it ain't just the thrill of a vacation spot. Anyone with half a brain knows real estate moves in waves, and right now, Whidbey Island's caught some serious momentum. You can't ignore the pull of natural beauty, access to city life, and that laid-back vibe that seems to whisper "slow down and...

Asia-Pacific Media Forum Eyes Future Growth Strategies

Media Heavyweights Converge in Shenzhen Picture this: Over 400 media moguls from the Asia-Pacific region, huddled together in Shenzhen under that blazing September sun. What for? They're on a mission, inspecting China's shifting landscape, hunting down fresh growth avenues in the Guangdong-Hong Kong-Macao Greater Bay Area. It kicks off within the walls of the Asia-Pacific...

Dr. Rashedi Reveals Laughing Gas Safety for Kids

Why Laughing Gas is a Game-Changer in Pediatric Dentistry You ever seen a kid freeze up like a deer in headlights at the dentist's office? I'm telling you, it's not just the sweet tooth nightmare but often the fear of that cold, intimidating chair. But let's talk about a game-changer: laughing gas or, known in the trade as nitrous oxide. Keeping Anxiety at Bay: The Role...

Iwa Robotics Unveils Autonomous Drone Wildfire Fleet

A Sky Full of Drones: A New Era for Wildfire Management Iwa Robotics is flipping the script on how we handle urban wildfires by rolling out a trio of drones straight out of an action movie: HAWK, CANARY, and PELICAN. These aren't just your run-of-the-mill flying machines. They're the latest tech-packed companions for our brave firefighters on the ground, designed...

PureHealth Research Spotlights Simpler Supplement Trends

What's Steering the Supplement Ship? Well, if you're paying any attention to the supplement space, you might've noticed something curious: folks are ditching complicated concoctions for good old fashioned simplicity. PureHealth Research, out of Manassas, is throwing the limelight on this trend, where people are handing in their multi-ingredient cocktail for a single...

Morpho Unveils Versatile UV Printer at IFA 2026

IFA 2026: A New Frontier for Desktop Printing You've seen your fair share of printers over the years, but when a company like Morpho steps onto the scene with a gadget that echoes innovation, it makes you perk up those market-ears. We're talking the big unveil of their desktop UV printer at the IFA 2026 in Berlin. Morpho's contraption isn't just spewing out ink; it's...

Ice-Rock Avalanches: Future Risks and Urgent Lessons

Mounting Threats in Mountain Chains That nightmare on August 26 at Mount Langtang Lirung in Nepal—where an ice-rock avalanche triggered a catastrophic mudslide—brought a harsh reminder that these mountains are cracking wide open. With 31 dead and over 500 souls still unaccounted for, it's a chilling warning about how vulnerable high-altitude regions have become. A...

See's Candies Data Breach Spurs Legal Scrutiny

Data Breach Hits See's Candies Hard Amidst Ransomware Attack Alright, folks, here's a not-so-sweet tale to kick off your day — See's Candies has found itself in a bit of a pickle. A ransomware attack, the nasty kind that makes you double-check your locks and your passwords, has reportedly exposed the personal data of its customers and employees. We're talking names,...

Affleck Joins Aflac in Unlikely Yet Fitting Alliance

A Partnership Born from a Punning Connection Look, in this world of insurance and Hollywood glitz, it's not every day you see Ben Affleck sharing the screen with a talking duck. But here we are. Aflac—the giant in supplemental health insurance—and Ben Affleck have cozied up for a series of ads under Affleck’s direction, breathing life into what started as nothing...